Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model

Transplantation

Volumn 69, Issue 3, 2000, Pages 450-454

  Yu, Cong ^a   Linsley, Peter ^c,d   Seidel, Kristy ^a   Sale, George ^a,b   Deeg, H Joachim ^a,b   Nash, Richard A ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d ROSETTA INPHARMATICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DOG; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0033998122     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002150-00027     Document Type: Article

References (39)

1. Storb R, Deeg HJ, Raff R, et al. Prevention of graft-versus-host disease: studies in a canine model. In: Bone marrow transplantation: foundations for the 21st century, Sackstein R, Janssen WE, Elfenbein GJ, eds. New York: Annals of the New York Academy of Sciences, 1995; 149
2. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
3. Ringdén O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094.
4. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759.
5. Storb R, RaffRF, Appelbaum FR, et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-non-identical donors. Transplantation 1993; 56: 800.
6. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303.
7. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634.
8. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249.
9. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197.
10. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048.
11. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581.
12. Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Hematopoietic cell transplantation, 2nd ed. Thomas ED, Blume KG, Forman SJ, eds. Boston: Blackwell Science, 1999; 287
13. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. In: ASCO education book. Perry MC, ed. Published by American Society of Clinical Oncology, Alexandria, VA with editorial and printing support from Lippincott, Williams & Wilkins, Baltimore, MD. 1999; 241.
14. McSweeney PA, Wagner JL, Maloney DG, et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant (Abstract). Blood 1998; 92(Suppl 1): 519a, 2133.
15. Woolfrey AE, Nash RA, Frangoul HA, et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T-cell immunodeficiency (Abstract). Blood 1998; 92(Suppl 1): 520a.
16. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
17. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721.
18. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
19. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701.
20. Ibrahim S, Jakobs F, Kittur D, et al. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood 1996; 88: 4594.
21. Wallace PM, Johnson JS, Macmaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment amerliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602.
22. Speiser DE, Bachmann MF, Shahinian A, Mak TW, Ohashi PS. Acute graft-versus-host disease without costimulation via CD28. Transplantation 1997; 63: 1042.
23. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
24. Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J.Exp.Med 1993; 178: 1801.
25. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
26. Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Transplantation 1996; 62: 1537.
27. Ladiges WC, Storb R, Graham T, Thomas ED. Experimental techniques used to study the immune system of dogs and other large animals. In: Methods of animal experimentation. Gay WI, Heavener JE, eds. New York: Academic Press, 1989; 103.
28. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens 1998; 52: 397.
29. Wagner JL, Burnett RC, Works JD, Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 1996; 48: 554.
30. Storb R, Deeg HJ. Failure of allogeneic canine marrow grafts after total body irradiation: Allogeneic "resistance" vs transfusion induced sensitization. Transplantation 1986; 42: 571.
31. Storb R, Graham TC, Shiurba R, Thomas ED. Treatment of canine graft-versus-host disease with methotrexate and cyclophosphamide following bone marrow transplantation from histoincompatible donors. Transplantation 1970; 10: 165.
32. Atkinson K, Shulman HM, Deeg HJ, et al. Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates: two distinct syndromes. Am J Pathol 1982; 108: 196.
33. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701.
34. Storer BE, Kim C. Exact properties of some exact test statistics for comparing two binomial proportions. J Am Stat Assoc 1990; 85: 146.
35. Weiner RS, Srinivas NR, Calore JD, Fadrowski CG, Shyu WC, Tay LK. A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. J Pharm Biomed Anal 1997; 15: 571.
36. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387.
37. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB-1. J Exp Med 1993; 177: 165.
38. Raff RF, Deeg HJ, Loughran TP Jr, et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood 1986; 68: 861.
39. Yu X-Z, Martin PJ, Anasetti C. Role of CD28 in acute graft-versus-host disease. Blood 1998; 92: 2963.